Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Übersichtsarbeit

Langwirksame Medikamente zur Behandlung der hyperkinetischen Störungen

1bearbeitete deutsche Version von Banaschewski et al., Long-acting medications for the hyperkinetic disorders; Eur Child Adolesc Psychiatry (2006); mit freundlicher Genehmigung des Springer-Verlags.

Eine systematische Übersicht und europäische Behandlungsleitlinien Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate

Published Online:March 24, 2008https://doi.org/10.1024/1422-4917.36.2.97

Abstract

Zusammenfassung: Ein Expertengremium aus mehreren europäischen Ländern hat sämtliche verfügbaren veröffentlichten und unveröffentlichten Studienergebnisse zum Einsatz von langwirksamen Medikamenten bei ADHS und hyperkinetischer Störung analysiert und auf dieser Grundlage praktische Empfehlungen zum Einsatz dieser Arzneimittel entwickelt. Im vorliegenden Artikel werden die Ergebnisse dieser Analyse dargestellt, in der die Wirksamkeit von Stimulanzien mit retardierter Freisetzung und Atomoxetin (ATX) anhand ihrer Effektstärken und der Anzahl der notwendigen Behandlungen (Numbers-Needed-to-Treat) verglichen werden. Auf der Grundlage der Analyse wurde gefolgert, (1) Langwirksame Präparate sollten zugelassen sein und eingesetzt werden; (2) Sie sollten kurzwirksame Arzneimittel (aus Kostengründen und wegen der höheren Flexibilität der Dosierung) nicht vollständig ersetzen. Individuelle Therapieoptionen sind erforderlich. (3) Sowohl ATX als auch Stimulanzien mit retardierter Freisetzung sollten zur Verfügung stehen.


Long-acting medications for the treatment of hyperkinetic disorders - A systematic review and European treatment guidelines. Part 2: A quantitative evaluation of long-acting medications

Summary: A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorders, on the basis of which practical recommendations for the application of these medications have been developed. The current article outlines results of this analysis, comparing the effect sizes and numbers-needed to-treat for extended-release stimulant preparations and atomoxetine (ATX). It is concluded (1) that long-acting preparations should be licensed and used. (2) However, they should not completely replace short-acting medications, in view of costs as well as the greater flexibility of dosing. Individual choices of therapy are necessary. (3) Both ATX and retarded-release stimulants should be available.

Literatur

  • Anlauf, M. (2006). Beurteilung von Therapien mit der «number needed to treat». Deutsches Ärzteblatt, 48, B2831– B2835 First citation in articleGoogle Scholar

  • Biederman, J. , Quinn, D. , Weiss, M. , Markabi, S. , Weidenman, M. , Edson, K. , Karlsson, G. , Pohlmann, H. , Wigal, S. (2003). Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatric Drugs, 5, 833– 841 First citation in articleCrossref Medline, Google Scholar

  • Clarke, S. A. , Eiser, C. (2004). The measurement of health-related quality of life (QoL) in paediatric clinical trials: a systematic review. Health and Quality of Life Outcomes, 2, 66– First citation in articleCrossref Medline, Google Scholar

  • Döpfner, M. , Banaschewski, T. , Schmidt, J. , Uebel, H. , Schmeck, K. , Gerber, W. D. , Günther, M. , Knölker, U. , Gehrke, M. , Häßler, F. , Resch, F. , Brünger, M. , Ose, C. , Fischer, R. , Poustka, A. , Rothenberger, A. , Lehmkuhl, G. (2003). Langzeitwirksames Methylphenidat bei Kindern mit Aufmerksamkeits- Hyperaktivitätsstörungen. Nervenheilkunde, 22, 85– 92 First citation in articleCrossref, Google Scholar

  • Döpfner, M. , Gerber, W. D. , Banaschewski, T. , Breuer, D. , Freisleder, F. J. , Gerber-von Muller, G. , Gunter, M. , Hassler, F. , Ose, C. , Rothenberger, A. , Schmeck, K. , Sinzig, J. , Stadler, C. , Uebel, H. , Lehmkuhl, G. (2004). Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. European Child Adolescent Psychiatry, 13, (Suppl 1) I93– 101 First citation in articleGoogle Scholar

  • Faraone, S. V. , Biederman, J. (2004). Using meta-analysis to draw conclusions about ADHD medication effects. 17th ECNP Congress. Stockholm First citation in articleGoogle Scholar

  • Faraone, S. V. , Biederman, J. , Spencer, T. , Aleardi, M. , META-ANALYSIS CTEOMFAU, (2006a). Comparing the efficacy of medications for ADHD using meta-analysis. Medscape General Medicine, 8, 4– First citation in articleMedline, Google Scholar

  • Faraone, S. V. , Biederman, J. , Spencer, T. , Aleardi, M. , Pagano, C. (2003). Using a meta-analysis to draw conclusions about ADHD medication effects (Poster). 156th Annual Meeting of the American Psychiatric Association. San Francisco, California First citation in articleGoogle Scholar

  • Faraone, S. V. , Spencer, T. , Aleardi, M. , Pagano, C. , Biederman, J. (2004). Metaanalysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. Journal of Clinical Psychopharmacology, 24, 24– 29 First citation in articleCrossref Medline, Google Scholar

  • Findling, R. L. , Quinn, D. , Hatch, S. , Cameron, S. , DeCory, H. , McDowell, M. (2006). Comparison of the clinical efficacy of twice-daily Ritalin®) and once-daily Equasym® XL with placebo in children with attention-deficit/hyperactivity disorder. European Child Adolescent Psychiatry, 15, (8) 450– 459 First citation in articleCrossref, Google Scholar

  • Geddes, J. , Butler, R. (2002). Depressive disorders. Clinical Evidence, 7, 867– 882 First citation in articleMedline, Google Scholar

  • Gonzalez, M. A. , Pentikis, H. S. , Anderl, N. , Benedict, M. F. , DeCory, H. H. , Dirksen, S. J. , Hatch, S. J. (2002). Methylphenidate bioavailability from two extended-release formulations. International Journal of Clinical Pharmacology Therapeutics, 40, 175– 184 First citation in articleCrossref Medline, Google Scholar

  • Greenhill, L. L. , Findling, R. L. , Swanson, J. M. (2002). A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 109, E39– First citation in articleCrossref Medline, Google Scholar

  • Kimko, H. C. , Cross, J. T. , Abernethy, D. R (1999). Pharmacokinetics and clinical effectiveness of methylphenidate. Clinical Pharmacokinetics, 37, 457– 470 First citation in articleCrossref Medline, Google Scholar

  • King, S. , Griffin, S. , Hodges, Z. , Weatherly, H. , Asseburg, C. , Richardson, G. , Golder, S. , Taylor, E. , Drummond, M. , Riemsma, R. (2004). Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children (commercial in confidence information removed). produced by the Centre for Reviews and Dissemination (CRD). www.nice.org.uk/pdf/ADHD_assessment_ report.pdf First citation in articleGoogle Scholar

  • Klassen, A. F. , Miller, A. , Fine, S. (2004). Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics, 114, e541– e547 First citation in articleCrossref Medline, Google Scholar

  • Leucht, S. , Pitschel-Walz, G. , Abraham, D. , Kissling, W. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51– 68 First citation in articleCrossref Medline, Google Scholar

  • Lopez, F. A. , Chandler, M. C. , Biederman, J. , Spencer, T. , Mays, D. A. , Michaels, M. A. , Tulloch, S. J. (2003b). Long-term Adderall XR treatment improves quality of life in ADHD children. 156th Annual Meeting of the American Psychiatric Association, San Francisco, California First citation in articleGoogle Scholar

  • Markowitz, J. S. , Straughn, A. B. , Patrick, K. S. , DeVane, C. L. , Pestreich, L. , Lee, J. , Wang, Y. , Muniz, R. (2003). Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clinical Pharmacokinetics, 42, 393– 401 First citation in articleCrossref Medline, Google Scholar

  • Matza, L. S. , Rentz, A. M. , Secnik, K. , Swensen, A. R. , Revicki, D. A. , Michelson, D. , Spencer, T. , Newcorn, J. H. , Kratochvil, C. J. (2004). The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. Journal of Developmental and Behavioral Pediatrics, 25, 166– 174 First citation in articleCrossref Medline, Google Scholar

  • Perwien, A. R. , Faries, D. E. , Kratochvil, C. J. , Sumner, C. R. , Kelsey, D. K. , Allen, A. J. (2004). Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics, 25, 264– 271 First citation in articleCrossref Medline, Google Scholar

  • Rentz, A. M. , Matza, L. S. , Secnik, K. , Swensen, A. , Revicki, D. A. (2005). Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attentiondeficit/hyperactivity disorder. Quality of Life Research, 14, 719– 734 First citation in articleCrossref Medline, Google Scholar

  • SIGN (Scottish Intercoligiate Guidelines Networt), (2004). A guidelines developer’s handbook. SIGN, Edinburgh First citation in articleGoogle Scholar

  • Sonuga-Barke, E. J. , Swanson, J. M. , Coghill, D. , DeCory, H. H. , Hatch, S. J. (2004). Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry, 4, 28– First citation in articleCrossref Medline, Google Scholar

  • Soomro, G. M. (2002). Obsessive-compulsive disorder. Clinical Evidence, 7, 896– 905 First citation in articleMedline, Google Scholar

  • Spencer, T. (2004). Safety and efficacy of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder (ODD). 157th Annual Meeting of the American Psychiatric Association, New York First citation in articleGoogle Scholar

  • Steele, M. , Weiss, M. , Swanson, J. , Wang, J. , Prinzo, R. , Binder, C. (2006). A randomized, controlled effectiveness trail of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in ADHD. Canaian Journal of Clinical Pharmacology, 13, e50– 62 First citation in articleMedline, Google Scholar

  • Stein, M. , A, , Sarampote, C. S. , Waldman, I. D. , Robb, A. S. , Conlon, C. , Pearl, P. L. , Black, D. O. , Seymour, K. E. , Newcorn, J. H. (2003). A dose-response study of OROS methylphenidate in children with attentiondeficit/ hyperactivity disorder. Pediatrics, 112, e404– First citation in articleCrossref Medline, Google Scholar

  • Swanson, J. , Greenhill, L. , Pelham, W. , Wilens, T. , Wolraich, M. , Abikoff, H. , Atkins, M. , August, G. , Biederman, J. , Bukstein, O. , Conners, C. K. , Efron, L. , Fiebelkorn, K. , Fried, J. , Hoffman, M. , Lambrecht, L. , Lerner, M. , Leventhal, B. , McBurnett, K. , Morse, E. , Palumbo, D. , Pfiffner, L. , Stein, M. , Wigal, S. B. , Winans, E. (2000). Initiating Concerta TM (Oros_ methylphenidate HCl) qu in children with attention-deficit hyperactivity disorder. Journal of Clinical Research, 3, 59– 76 First citation in articleGoogle Scholar

  • Swanson, J. , Gupta, S. , Lam, A. , Shoulson, I. , Lerner, M. , Modi, N. , Lindemulder, E. , Wigal, S. (2003). Development of a new once-a-day formulation of methylphenidate for the treatment of attentiondeficit/hyperactivity disorder: proof-ofconcept and proof-of-product studies. Archives of General Psychiatry, 60, 204– 211 First citation in articleCrossref Medline, Google Scholar

  • Swanson, J. M. , Wigal, S. B. , Wigal, T. , Sonuga-Barke, E. , Greenhill, L. L. , Biederman, J. , Kollins, S. , Nguyen, A. S. , DeCory, H. H. , Hirshe Dirksen, S. J. , Hatch, S. J. (2004). A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics, 113, e206– e216 First citation in articleCrossref Medline, Google Scholar

  • Weiss, M. , Tannock, R. , Kratochvil, C. , Dunn, D. , Velez-Borras, J. , Thomason, C. , Tamura, R. , Kelsey, D. , Stevens, L. , Allen, A. J. (2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 64– 655 First citation in articleCrossref Medline, Google Scholar

  • Wolraich, M. L. , Greenhill, L. L. , Pelham, W. , Swanson, J. , Wilens, T. , Palumbo, D. , Atkins, M. , McBurnett, K. , Bukstein, O. , August, G. (2001). Randomized, controlled trial of oros methylphenidate once a day in children with attention deficit/ hyperactivity disorder. Pediatrics, 108, 883– 892 First citation in articleCrossref Medline, Google Scholar